Mass Spectrometry (LC-MS/MS) Site-Mapping of N-Glycosylated Membrane Proteins for Breast Cancer Biomarkers

Revlon/UCLA Breast Center, Department of Surgery, Neuropsychiatric Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles, California 90095, USA.
Journal of Proteome Research (Impact Factor: 4.25). 07/2009; 8(8):4151-60. DOI: 10.1021/pr900322g
Source: PubMed


Cancer cell membrane proteins are released into the plasma/serum by exterior protein cleavage, membrane sloughing, cellular secretion or cell lysis, and represent promising candidates for interrogation. Because many known disease biomarkers are both glycoproteins and membrane bound, we chose the hydrazide method to specifically target, enrich, and identify glycosylated proteins from breast cancer cell membrane fractions using the LTQ Orbitrap mass spectrometer. Our initial goal was to select membrane proteins from breast cancer cell lines and then to use the hydrazide method to identify the N-linked proteome as a prelude to evaluation of plasma/serum proteins from cancer patients. A combination of steps facilitated identification of the glycopeptides and also defined the glycosylation sites. In MCF-7, MDA-MB-453 and MDA-MB-468 cell membrane fractions, use of the hydrazide method facilitated an initial enrichment and site mapping of 27 N-linked glycosylation sites in 25 different proteins. However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines. In addition, MCF-7 cells shared an additional 3 proteins with MDA-MB-453. Interestingly, the hydrazide method isolated a number of other N-linked glycoproteins also known to be involved in breast cancer, including epidermal growth factor receptor (EGFR), CD44, and the breast cancer 1, and early onset isoform 1 (BRCA1) biomarker. Analyzing the N-glycoproteins from membranes of breast cancer cell lines highlights the usefulness of the procedure for generating a practical set of potential biomarkers.

Download full-text


Available from: Julian Philip Whitelegge,
  • Source
    • "selectively enriches glycopeptides exposed to the cell exterior was applied to monitor dynamic protein changes in the cell surface glycoproteome of Drosophila melanogaster cells . Hy - drazide - based capturing approaches coupled label - free quantifi - cation mass spectrometry have also been tried for biomarker discovery targeting breast cancer ( Whelan et al . , 2009 ) , lung cancer ( Zeng et al . , 2010a ) , and HCC ( Chen et al . , 2011 ; Ishihara et al . , 2011 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Mass spectrometry (MS) has been a core technology for high sensitive and high-throughput analysis of the enriched glycoproteome in aspects of quantitative assays as well as qualitative profiling of glycoproteins. Because it has been widely recognized that aberrant glycosylation in a glycoprotein may involve in progression of a certain disease, the development of efficient analysis tool for the aberrant glycoproteins is very important for deep understanding about pathological function of the glycoprotein and new biomarker development. This review first describes the protein glycosylation-targeting enrichment technologies mainly employing solid-phase extraction methods such as hydrizide-capturing, lectin-specific capturing, and affinity separation techniques based on porous graphitized carbon, hydrophilic interaction chromatography, or immobilized boronic acid. Second, MS-based quantitative analysis strategies coupled with the protein glycosylation-targeting enrichment technologies, by using a label-free MS, stable isotope-labeling, or targeted multiple reaction monitoring (MRM) MS, are summarized with recent published studies. © 2014 The Authors. Mass Spectrometry Reviews Published by Wiley Periodicals, Inc. Rapid Commun. Mass Spectrom.
    Mass Spectrometry Reviews 04/2015; 34(2). DOI:10.1002/mas.21428 · 7.71 Impact Factor
  • Source
    • "Among these, the most powerful one is mass spectrometry, which has already been frequently applied in glycobiology [5,6]. Mass spectrometry has already been successfully applied for the analysis of glycans on the cell membrane [7-10]. However, the sophistication of the membrane glycan enrichment procedure and the mass spectrometry analysis itself make it not easy for wide applications. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is well known that cell surface glycans or glycocalyx play important roles in sperm motility, maturation and fertilization. A comprehensive profile of the sperm surface glycans will greatly facilitate both basic research (sperm glycobiology) and clinical studies, such as diagnostics of infertility. As a group of natural glycan binders, lectin is an ideal tool for cell surface glycan profiling. However, because of the lack of effective technology, only a few lectins have been tested for lectin-sperm binding profiles. To address this challenge, we have developed a procedure for high-throughput probing of mammalian sperm with 91 lectins on lectin microarrays. Normal sperm from human, boar, bull, goat and rabbit were collected and analyzed on the lectin microarrays. Positive bindings of a set of ~50 lectins were observed for all the sperm of 5 species, which indicated a wide range of glycans are on the surface of mammalian sperm. Species specific lectin bindings were also observed. Clustering analysis revealed that the distances of the five species according to the lectin binding profiles are consistent with that of the genome sequence based phylogenetic tree except for rabbit. The procedure that we established in this study could be generally applicable for sperm from other species or defect sperm from the same species. We believe the lectin binding profiles of the mammalian sperm that we established in this study are valuable for both basic research and clinical studies.
    Clinical Proteomics 03/2014; 11(1):10. DOI:10.1186/1559-0275-11-10
  • Source
    • "Glycosylation assays using canine pancreas membranes have shown that the certain amino acids (W, D, E and L) at the x position of NxS sequons strongly reduce glycosylation efficiency (Shakin-Eshleman et al., 1996). It is unclear why HeLa cell ZAG and human serum ZAG lack one of the glycans on the adjacent NxS sites whereas ZAG synthesized by two other cell types is modified on both the N 109 DS and N 112 GS sequons (Ramachandran et al., 2006; Whelan et al., 2009). It should be noted that glycoproteomic detection of the diglycosylated ZAG glycopeptide does not indicate that the predominant ZAG glycoform is modified on both sites. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Asparagine linked glycosylation of proteins by the oligosaccharyltransferse (OST) occurs when acceptor sites or sequons (N-X≠P-T/S) on nascent polypeptides enter the lumen of the rough endoplasmic reticulum. Metazoan organisms assemble two isoforms of the oligosaccharyltransferase that have different catalytic subunits (STT3A or STT3B) and partially non-overlapping cellular roles. Potential glycosylation sites move past the translocation channel associated STT3A complex at the protein synthesis elongation rate. Here, we have investigated whether close spacing between acceptor sites in a nascent protein promotes site skipping by the STT3A complex. Biosynthetic analysis of four human glycoproteins revealed that closely spaced sites are efficiently glycosylated by an STT3B-independent process unless the sequons contain non-optimal sequence features including extreme close spacing between sequons (e.g., NXTNXT) or the presence of paired NXS sequons (e.g., NXSANXS). Many, but not all, glycosylation sites that are skipped by the STT3A complex can be glycosylated by the STT3B complex. Analysis of a murine glycoprotein database revealed that closely spaced sequons are surprisingly common, and are enriched for paired NXT sites when the gap between sequons is less than three residues.
    Journal of Cell Science 10/2013; 126(23). DOI:10.1242/jcs.139584 · 5.43 Impact Factor
Show more